secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zura Bio Ltd (ZURA)
CIK:        0001855644
Form:       8-K
Filed at:   2022-12-12T23:59:59+00:00
Accession:  0001104659-22-126265
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

JATT grants Eli Lilly 550,000 shares for IL-33 license; contingent on Zura merger
--------------------------------------------------------------------------------

- JATT granted Eli Lilly 550,000 Class A shares as partial consideration for Lilly licensing an IL-33 compound to Z33, a Zura subsidiary.
- Shares issued in a private placement exempt from registration under Section 4(a)(2) of the Securities Act.
- Shares subject to staggered lock-up: one-third restricted for 6, 12, and 24 months post-closing, with early release if stock hits $12 for 20 of 30 trading days.
- Equity Grant closing contingent on completion of JATT's business combination with Zura Bio.
- Lilly entered into a License Agreement with Z33 on December 8, 2022 for the compound.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855644/000110465922126265/0001104659-22-126265-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855644/000110465922126265/tm2232433d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-126265

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer